In China, clinical trials of favipiravir were successfully completed, immediately after which the Chinese pharmaceutical company received permission to mass-produce the drug.
Favipiravir is an antiviral drug developed in Japan by Toyama Chemical (holding Fujifilm ) in 648 - m year and approved for clinical use in Japan in 1998 year. It is active against RNA viruses.
The drug showed good clinical efficacy against a new coronavirus disease, and also, according to Zhang Xinmin ( Chinese 张新民, English Zhang Xinmin) , Director of China National Center for Biotechnology Development under the Ministry of Science and Technology ( China. 科技部 中国 生物 技术 发展 中心) , the drug showed no serious side effects.
Clinical trials of Favipiravir were conducted at the Shenzhen Third People’s Hospital. Participated 35 patients, 22 of them took Favipiravir, and the rest 35 patients were in the control group. Patients treated with Favipiravir therapy recovered (that is, they were no longer detected when the virus was retested) in a shorter time period compared with patients in the control group.
A large randomized clinical trial conducted by Zhongnan Hospital at Wuhan University ( China. 武汉 大学) also revealed positive therapeutic effect of favipiravir. Favipiravir was recommended by Chinese doctors and will be included in the treatment instructions COVID - 19 . A Chinese pharmaceutical company received a license from the National Administration for the Production of Drugs for the mass production of the drug.
The fact that the drug was included in the list of Chinese recommendations for the treatment of infection and put on serial production, suggests that at least he will have a large clinical base of treatment results, which at the moment no drug is tested for exposure to coronavirus. However, first-line medication recommended in other countries may differ from that for China. South Korea, for example, refused to use favipiravir, considering the data obtained about it in the tests it conducted to be insufficient.
In the fight against the new coronavirus in China, some other technologies, including stem cell therapy, which may be effective in reducing the intensity of severe inflammatory reactions caused by infection. China has initiated several clinical research programs for this treatment. The country is also trying to use the technology of artificial blood purification (“artificial liver”) to work with critically ill patients.